Expressão cutânea das β-defensinas (cBD102 e cBD103) em cães acometidos por leishmaniose visceral

• Ano de defesa: 2012
• Autor(a) principal: Hernandez, Fernely Augusto Plazas
• Orientador(a): Conceição, Lissandro Gonçalves
• Banca de defesa: Bicalho, Adriane Pimenta da Costa Val , Viloria, Marlene Isabel Vargas
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Viçosa
• Programa de Pós-Graduação: Mestrado em Medicina Veterinária
• Departamento: Biotecnologia, diagnóstico e controle de doenças; Epidemiologia e controle de qualidade de prod. de
• País: BR
• Palavras-chave em Português: Cães; Leishmaniose; Beta defensinas
• Palavras-chave em Inglês: Dogs; Leishmaniasis; Beta defensins
• Área do conhecimento CNPq: CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::PATOLOGIA ANIMAL::ANATOMIA PATOLOGIA ANIMAL
• Link de acesso: http://locus.ufv.br/handle/123456789/5136

In response to an infection, blood cells such as neutrophils produce defensins within minutes to two hours to aid pathogens lysis and stimulate chemotaxis, reaching peak levels in the body in 24 hours. These peptides can also be produced without any stimulus by epithelial cells of the integumentary system. The aim of this work was to study the expression of β-defensins (cBD102 and cBD103) of canine skin diagnosed with canine visceral leishmaniasis (CVL). There were selected 43 skin samples from dogs positive to CVL and healthy, they were included in paraffin blocks and divided into three groups: I desquamative dermatitis (DD) with 16 blocks, II ulcerative dermatitis (UD) 21 blocks and the control group (6 blocks without canine skin problems). It was used the indirect immunoperoxidase technique (IIP) to confirm the LVC diagnosis and the identification of β-defensins, using human primary antibodies (hBD-2 and hBD-3, SIGMA®). The experimental delineation was completely casualized, with a confidence level of 0.95. Note that there was difference (p = 0.03) in the immunostaining intensity between groups, showing higher marcation intensity with cBD102 and cBD103 in the epidermis of the control group compared with DD and DU groups. In the dermis there was difference (p = 0.001) of the two β-defensins studied, being the cBD103 expression higher than the cBD102. This study is the first one relating to the immunological interaction of the extension and intensity expression between the β-defensin cBD102 and cBD103 and canine visceral leishmaniasis in the DD and DU dermatological standards, assessed by immunohistochemistry.